Breakthrough study reveals Delcath Systems’ therapy doubles survival for uveal melanoma patients

Pallavi Madhiraju- August 29, 2024 0

Delcath Systems, Inc. (Nasdaq: DCTH), a pioneering company in interventional oncology, has announced promising results from a recent independent study evaluating its liver-directed therapy for ... Read More

TriSalus Life Sciences’ SD-101 yields positive outcomes from Phase 1 trial in uveal melanoma with liver metastases

Pallavi Madhiraju- November 5, 2023 0

TriSalus Life Sciences made a significant contribution to the Society of Immunotherapy for Cancer (SITC) 2023 Annual Meeting by revealing additional data from its Phase ... Read More